Persistent binding at dopamine transporters determines sustained psychostimulant effects.

Area of Science:

• Neuroscience
• Pharmacology
• Medicinal Chemistry

Background:

• Psychostimulants targeting the dopamine transporter (DAT) have therapeutic and illicit uses.
• Adverse events associated with psychostimulants can be severe and persistent.
• In vitro pharmacological properties often do not accurately predict in vivo effects.

Purpose of the Study:

• To investigate the in vitro and in vivo pharmacological effects of pyrovalerone analogs.
• To compare the action of pyrovalerone enantiomers with traditional psychostimulants like cocaine and methylphenidate.
• To determine the relationship between drug-binding kinetics at DAT and in vivo psychostimulant action.

Main Methods:

• In vitro binding assays to assess drug interactions with DAT.
• Computational modeling to analyze drug-target interactions.
• In vivo behavioral studies in mice to evaluate psychostimulant effects.
• Kinetic analysis of drug-DAT dissociation (koff).

Main Results:

• In vitro drug-binding kinetics at DAT correlated with the time-course of in vivo psychostimulant action.
• Slow dissociation (slow koff) of S-enantiomers of pyrovalerone analogs from DAT predicted more persistent in vivo effects.
• Pyrovalerone analogs exhibited different in vivo profiles compared to cocaine and methylphenidate.

Conclusions:

• Drug-binding kinetics at DAT are critical for determining the in vivo effects of psychostimulant drugs.
• Slow dissociation from DAT is a key factor contributing to the prolonged action of certain psychostimulants.
• Understanding these kinetics can inform the development of safer and more effective psychostimulant medications.